Alglucosidase Alfa Temporary Access Program
ATAP
1 other identifier
expanded_access
N/A
1 country
74
Brief Summary
Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The objective of this expanded access study is to provide patients with Pompe disease in the United States (US), access to alglucosidase alfa produced from a scaled up manufacturing process for a limited time until production at this scale is approved for commercial use by the Food and Drug Administration.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
74 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 21, 2007
CompletedFirst Posted
Study publicly available on registry
August 23, 2007
CompletedFebruary 6, 2014
February 1, 2014
August 21, 2007
February 4, 2014
Conditions
Keywords
Interventions
IV infusion: 20mg/kg qow
Eligibility Criteria
You may qualify if:
- The patient or patient's legal guardian must provide signed, informed consent prior to performing any study-related procedures.
- The patient must reside in the US.
- The patient must have a confirmed diagnosis of Pompe disease defined as documented acid alpha-glucosidase (GAA) enzyme deficiency from any tissue source and/or GAA gene mutations.
- The patient must have/had documented clinical signs and symptoms of Pompe disease.
- The patient must have/had prior treatment with alglucosidase alfa produced at commercial scale OR be naive to enzyme replacement therapy (ERT) for the treatment of Pompe disease and meet at least 1 of the following criteria: require a wheelchair OR require some respiratory assistance for any number of hours (including night time) through non-invasive ventilation.
- The patient must be capable of complying with the required program schedule of assessments.
You may not qualify if:
- Females who are pregnant or lactating
- The patient has a clinical condition unrelated to Pompe disease that would interfere with program assessments.
- The patient is currently enrolled in any clinical studies.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (74)
Unknown Facility
Sheffield, Alabama, United States
Unknown Facility
Anchorage, Alaska, United States
Unknown Facility
Phoenix, Arizona, United States
Unknown Facility
Prescott, Arizona, United States
Unknown Facility
Scottsdale, Arizona, United States
Unknown Facility
Tucson, Arizona, United States
Unknown Facility
Bakersfield, California, United States
Unknown Facility
Beverly Hills, California, United States
Unknown Facility
Loma Linda, California, United States
Unknown Facility
Los Angeles, California, United States
Unknown Facility
Sacramento, California, United States
Unknown Facility
San Diego, California, United States
Unknown Facility
Stanford, California, United States
Unknown Facility
Aurora, Colorado, United States
Unknown Facility
Washington D.C., District of Columbia, United States
Unknown Facility
Bradenton, Florida, United States
Unknown Facility
Coral Springs, Florida, United States
Unknown Facility
Daytona Beach, Florida, United States
Unknown Facility
Gainsville, Florida, United States
Unknown Facility
St. Petersburg, Florida, United States
Unknown Facility
Decatur, Georgia, United States
Unknown Facility
Boise, Idaho, United States
Unknown Facility
Chicago, Illinois, United States
Unknown Facility
Evansville, Indiana, United States
Unknown Facility
Iowa City, Iowa, United States
Unknown Facility
Kansas City, Kansas, United States
Unknown Facility
Louisville, Kentucky, United States
Unknown Facility
New Orleans, Louisiana, United States
Unknown Facility
Shreveport, Louisiana, United States
Unknown Facility
Augusta, Maine, United States
Unknown Facility
Baltimore, Maryland, United States
Unknown Facility
Boston, Massachusetts, United States
Unknown Facility
Springfield, Massachusetts, United States
Unknown Facility
Detroit, Michigan, United States
Unknown Facility
Grand Rapids, Michigan, United States
Unknown Facility
Lake Orion, Michigan, United States
Unknown Facility
Rochester Hills, Michigan, United States
Unknown Facility
Saint Joseph, Michigan, United States
Unknown Facility
Minneapolis, Minnesota, United States
Unknown Facility
Missoula, Montana, United States
Unknown Facility
Omaha, Nebraska, United States
Unknown Facility
Midland Park, New Jersey, United States
Unknown Facility
Albuquerque, New Mexico, United States
Unknown Facility
Albany, New York, United States
Unknown Facility
Corning, New York, United States
Unknown Facility
Manhasset, New York, United States
Unknown Facility
New York, New York, United States
Unknown Facility
Asheville, North Carolina, United States
Unknown Facility
Durham, North Carolina, United States
Unknown Facility
Jacksonville, North Carolina, United States
Unknown Facility
Cincinnati, Ohio, United States
Unknown Facility
Cleveland, Ohio, United States
Unknown Facility
Greenville, Ohio, United States
Unknown Facility
Toledo, Ohio, United States
Unknown Facility
Oklahoma City, Oklahoma, United States
Unknown Facility
Tulsa, Oklahoma, United States
Unknown Facility
Portland, Oregon, United States
Unknown Facility
Philadelphia, Pennsylvania, United States
Unknown Facility
Pittsburgh, Pennsylvania, United States
Unknown Facility
Greenville, South Carolina, United States
Unknown Facility
West Colombia, South Carolina, United States
Unknown Facility
Houston, Texas, United States
Unknown Facility
San Antonio, Texas, United States
Unknown Facility
Waco, Texas, United States
Unknown Facility
Salt Lake City, Utah, United States
Unknown Facility
Charlottesville, Virginia, United States
Unknown Facility
Chesapeake, Virginia, United States
Unknown Facility
Newport News, Virginia, United States
Unknown Facility
Richmond, Virginia, United States
Unknown Facility
Winchester, Virginia, United States
Unknown Facility
Pullman, Washington, United States
Unknown Facility
Seattle, Washington, United States
Unknown Facility
Morgantown, West Virginia, United States
Unknown Facility
Green Bay, Wisconsin, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Medical Monitor
Genzyme, a Sanofi Company
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 21, 2007
First Posted
August 23, 2007
Last Updated
February 6, 2014
Record last verified: 2014-02